跳至主要内容
临床试验/NCT01241487
NCT01241487已完成4 期

An 8 Weeks Open Label National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy

Novartis1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2009年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
入组人数
150
试验地点
1
主要终点
Hypertension in patients that will be controlled on each concentration and those that will switch to the higher concentration (160/10)

研究概览

简要总结

This study is to assess the efficacy of the fixed combination of Valsartan and Amlodipine in hypertensive patients uncontrolled by monotherapy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient uncontrolled by mono-therapy for at least 8 weeks, having B.P.>/= 140/90 mmHg in non diabetics or >/= 130/80 mmHg in diabetics

排除标准

  • Patient having B.P.>= 180/110 mmHg in non diabetics or >= 160/100 mmHg in diabetics
  • Type 1 Diabetes or uncontrolled type 2 Diabetes.
  • PCI in last 12 months.
  • Concomitant unstable angina. Other protocol-defined inclusion/exclusion criteria may apply

研究组 & 干预措施

1

Experimental

valsartan/amlodipine

干预措施: valsartan/amlodipine (Drug)

结局指标

主要结局

Hypertension in patients that will be controlled on each concentration and those that will switch to the higher concentration (160/10)

时间窗: 4 weeks

次要结局

  • The incidence of Edema(8 weeks)
  • Hypertension of patients that were previously controlled on (160/5) and those that were uncontrolled and switched to the higher concentration (160/10) after 4 weeks on (160/5) concentration.(8 weeks)
  • Safety and Tolerability of the Trial Medication(8 weeks)

研究者

发起方
Novartis
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验